Cancer Treatment

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

The deal would bring Halda’s RIPTAC technology plus prostate cancer pill HLD-0915 under J&J pending antitrust clearance.